Activating killer cell Ig-like receptors in health and disease

Frontiers in Immunology

Volumn 5, Issue APR, 2014, Pages

  Ivarsson, Martin A ^a   Michaëlsson, Jakob ^a   Fauriat, Cyril ^b,c,d,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e CNRS   (France)

Author keywords

Autoimmune diseases; Cancer; Education; HLA; Infection diseases; KIR; NK cells; Pregnancy

Indexed keywords

HLA ANTIGEN CLASS 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; LIGAND;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; HUMAN; INFECTION; NATURAL KILLER CELL; NEOPLASM; PREGNANCY; PROTEIN EXPRESSION; RECEPTOR ACTIVATION; RECEPTOR BINDING; REPRODUCTION; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION;

EID: 84900867577     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00184     Document Type: Review

References (106)

1. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol (1975) 5:112-7. doi: 10.1002/eji.1830050208.
2. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer (1975) 16:230-9. doi:10.1002/ijc.2910160205.
3. Trinchieri G, Santoli D, Dee RR, Knowles BB. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Identification of the anti-viral activity as interferon and characterization of the human effector lymphocyte subpopulation. J Exp Med (1978) 147:1299-313. doi:10.1084/jem.147.5.1299.
4. Becker S, Kiessling R, Lee N, Klein G. Modulation of sensitivity to natural killer cell lysis after in vitro explantation of a mouse lymphoma. J Natl Cancer Inst (1978) 61:1495-8.
5. Piontek GE, Taniguchi K, Ljunggren HG, Grönberg A, Kiessling R, Klein G, et al. YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol (1985) 135:4281-8.
6. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 319:675-8. doi:10.1038/319675a0.
7. Karlhofer FM, Ribaudo RK, Yokoyama WM. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature (1992) 358:66-70. doi:10.1038/358066a0.
8. Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med (1993) 178:597-604. doi:10.1084/jem.178.2.597.
9. Moretta A, Tambussi G, Bottino C, Tripodi G, Merli A, Ciccone E, et al. A novel surface antigen expressed by a subset of human CD3- CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med (1990) 171:695-714. doi:10.1084/jem.171.3.695.
10. Moretta A, Bottino C, Pende D, Tripodi G, Tambussi G, Viale O, et al. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med (1990) 172:1589-98. doi:10.1084/jem.172.6.1589.
11. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med (1994) 180:537-43. doi:10.1084/jem.180.2.537.
12. Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R, et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med (1995) 182:875-84. doi:10.1084/jem.182.3.875.
13. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science (1995) 268:405-8. doi:10.1126/science.7716543.
14. Morvan M, David G, Sébille V, Perrin A, Gagne K, Willem C, et al. Autologous and allogeneic HLA KIR ligand environments and activating KIR control KIR NK-cell functions. Eur J Immunol (2008) 38:3474-86. doi:10.1002/eji.200838407.
15. Fauriat C, Ivarsson MA, Ljunggren H-G, Malmberg K-J, Michaëlsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood (2010) 115:1166-74. doi:10.1182/blood-2009-09-245746.
16. David G, Morvan M, Gagne K, Kerdudou N, Willem C, Devys A, et al. Discrimination between the main activating and inhibitory killer cell immunoglobulin-like receptor positive natural killer cell subsets using newly characterized monoclonal antibodies. Immunology (2009) 128:172-84. doi:10.1111/j.1365-2567.2009.03085.x.
17. Béziat V, Liu LL, Malmberg J-A, Ivarsson MA, Sohlberg E, Björklund AT, et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood (2013) 121:2678-88. doi:10.1182/blood-2012-10-459545.
18. Liu J, Xiao Z, Ko HL, Shen M, Ren EC. Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11. Proc Natl Acad Sci U S A (2014) 111:2662-7. doi:10.1073/pnas.1322052111.
19. VandenBussche CJ, Mulrooney TJ, Frazier WR, Dakshanamurthy S, Hurley CK. Dramatically reduced surface expression of NK cell receptor KIR2DS3 is attributed to multiple residues throughout the molecule. Genes Immun (2009) 10:162-73. doi:10.1038/gene.2008.91.
20. Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, Older Aguilar AM, et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med (2009) 206:2557-72. doi:10.1084/jem.20091010.
21. Steiner NK, Dakshanamurthy S, VandenBussche CJ, Hurley CK. Extracellular domain alterations impact surface expression of stimulatory natural killer cell receptor KIR2DS5. Immunogenetics (2008) 60:655-67. doi:10.1007/s00251-008-0322-2.
22. Della Chiesa M, Romeo E, Falco M, Balsamo M, Augugliaro R, Moretta L, et al. Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function. Eur J Immunol (2008) 38:2284-9. doi:10.1002/eji.200838434.
23. Czaja K, Borer A-S, Schmied L, Terszowski G, Stern M, Gonzalez A. A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs. Genes Immun (2013) 15(1):33-7. doi:10.1038/gene.2013.58.
24. Carr WH, Rosen DB, Arase H, Nixon DF, Michaëlsson J, Lanier LL. Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol (2007) 178:647-51.
25. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol (2008) 180:3969-79.
26. Apps R, Gardner L, Moffett A. A critical look at HLA-G. Trends Immunol (2008) 29:313-21. doi:10.1016/j.it.2008.02.012.
27. Cisneros E, Moraru M, Gómez-Lozano N, López-Botet M, Vilches C. KIR2DL5: an orphan inhibitory receptor displaying complex patterns of polymorphism and expression. Front Immunol (2012) 3:289. doi:10.3389/fimmu.2012.00289.
28. Stern M, Ruggeri L, Capanni M, Mancusi A, Velardi A. Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood (2008) 112:708-10. doi:10.1182/blood-2008-02-137521.
29. Dohring C, Scheidegger D, Samaridis J, Cella M, Colonna M. A human killer inhibitory receptor specific for HLA-A1,2. J Immunol (1996) 156(9):3098-101.
30. Pende D, Biassoni R, Cantoni C, Verdiani S, Falco M, di Donato C, et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med (1996) 184:505-18. doi:10.1084/jem.184.2.505.
31. Trundley AE, Hiby SE, Chang C, Sharkey AM, Santourlidis S, Uhrberg M, et al. Molecular characterization of KIR3DL3. Immunogenetics (2006) 57:904-16. doi:10.1007/s00251-005-0060-7.
32. Parham P, Norman PJ, Abi-Rached L, Guethlein LA. Variable NK cell receptors exemplified by human KIR3DL1/S1. J Immunol (2011) 187:11-9. doi:10.4049/jimmunol.0902332.
33. Takeshita LYC, Gonzalez-Galarza FF, dos Santos EJM, Maia MHT, Rahman MM, Zain SMS, et al. A database for curating the associations between killer cell immunoglobulin-like receptors and diseases in worldwide populations. Database (Oxford) (2013) 2013:bat021. doi:10.1093/database/bat021.
34. Pascal V, Yamada E, Martin MP, Alter G, Altfeld M, Metcalf JA, et al. Detection of KIR3DS1 on the cell surface of peripheral blood NK cells facilitates identification of a novel null allele and assessment of KIR3DS1 expression during HIV-1 infection. J Immunol (2007) 179:1625-33.
35. Trundley A, Frebel H, Jones D, Chang C, Trowsdale J. Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. Eur J Immunol (2007) 37:780-7. doi:10.1002/eji.200636773.
36. Morvan M, Willem C, Gagne K, Kerdudou N, David G, Sebille V, et al. Phenotypic and functional analyses of KIR3DL1+ and KIR3DS1+ NK cell subsets demonstrate differential regulation by Bw4 molecules and induced KIR3DS1 expression on stimulated NK cells. J Immunol (2009) 182:6727-35. doi:10.4049/jimmunol.0900212.
37. Cognet C, Farnarier C, Gauthier L, Frassati C, André P, Magérus-Chatinet A, et al. Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells. Clin Immunol (2010) 135:26-32. doi:10.1016/j.clim.2009.12.009.
38. O'Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol (2007) 178:235-41.
39. Rajagopalan S, Long EO. KIR2DL4 (CD158d): an activation receptor for HLA-G. Front Immunol (2012) 3:258. doi:10.3389/fimmu.2012.00258.
40. Goodridge JP, Witt CS, Christiansen FT, Warren HS. KIR2DL4 (CD158d) genotype influences expression and function in NK cells. J Immunol (2003) 171:1768-74.
41. Kikuchi-Maki A, Yusa S-I, Catina TL, Campbell KS. KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J Immunol (2003) 171:3415-25.
42. David G, Djaoud Z, Willem C, Legrand N, Rettman P, Gagne K, et al. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 specificity of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation. J Immunol (2013) 191:4778-88. doi:10.4049/jimmunol.1301580.
43. Stewart CA, Laugier-Anfossi F, Vély F, Saulquin X, Riedmuller J, Tisserant A, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A (2005) 102:13224-9. doi:10.1073/pnas.0503594102.
44. Moesta AK, Parham P. Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. Front Immunol (2012) 3:336. doi:10.3389/fimmu.2012.00336.
45. Rajagopalan S, Long EO. The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity. J Exp Med (1997) 185:1523-8. doi:10.1084/jem.185.8.1523.
46. Katz G, Gazit R, Arnon TI, Gonen-Gross T, Tarcic G, Markel G, et al. MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol (2004) 173:1819-25.
47. Smith HRC, Heusel JW, Mehta IK, Kim S, Dorner BG, Naidenko OV, et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A (2002) 99:8826-31. doi:10.1073/pnas.092258599.
48. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science (2002) 296:1323-6. doi:10.1126/science.1070884.
49. Kielczewska A, Pyzik M, Sun T, Krmpotic A, Lodoen M, Munks M, et al. Ly49P recognition of cytomegalovirus-infected cells expressing H2-Dk and CMV-encoded m04 correlates with the NK cell antiviral response. J Exp Med (2009) 206(3):515-23. doi:10.1084/jem.20080954.
50. Fadda L, Borhis G, Ahmed P, Cheent K, Pageon SV, Cazaly A, et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A (2010) 107:10160-5. doi:10.1073/pnas.0913745107.
51. Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H, et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol (2004) 34(6):1673-9. doi:10.1002/eji.200425089.
52. Lu X, Gibbs JS, Hickman HD, David A, Dolan BP, Jin Y, et al. Endogenous viral antigen processing generates peptide-specific MHC class I cell-surface clusters. Proc Natl Acad Sci U S A (2012) 109:15407-12. doi:10.1073/pnas.1208696109.
53. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature (1998) 391:703-7. doi:10.1038/35642.
54. Olcese L, Cambiaggi A, Semenzato G, Bottino C, Moretta A, Vivier E. Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. J Immunol (1997) 158:5083-6.
55. Turnbull IR, Colonna M. Activating and inhibitory functions of DAP12. Nat Rev Immunol (2007) 7:155-61. doi:10.1038/nri2014.
56. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med (2007) 204:3027-36. doi:10.1084/jem.20070695.
57. Biassoni R, Pessino A, Malaspina A, Cantoni C, Bottino C, Sivori S, et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol (1997) 27:3095-9. doi:10.1002/eji.1830271203.
58. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol (2007) 179:854-68.
59. Pittari G, Liu X-R, Selvakumar A, Zhao Z, Merino E, Huse M, et al. NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand. J Immunol (2013) 190(9):4650-60. doi:10.4049/jimmunol.1202120.
60. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song Y-J, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature (2005) 436:709-13. doi:10.1038/nature03847.
61. Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 25:331-42. doi:10.1016/j.immuni.2006.06.013.
62. Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood (2005) 106:1711-7. doi:10.1182/blood-2005-03-0918.
63. Sun JC, Lanier LL. Tolerance of NK cells encountering their viral ligand during development. J Exp Med (2008) 205:1819-28. doi:10.1084/jem.20072448.
64. Narni-Mancinelli E, Jaeger BN, Bernat C, Fenis A, Kung S, De Gassart A, et al. Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses. Science (2012) 335:344-8. doi:10.1126/science.1215621.
65. Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol (2005) 5:363-74. doi:10.1007/s11626-013-9593-5.
66. Bolanos FD, Tripathy SK. Activation receptor-induced tolerance of mature NK cells in vivo requires signaling through the receptor and is reversible. J Immunol (2011) 186:2765-71. doi:10.4049/jimmunol.1003046.
67. Joncker NT, Shifrin N, Delebecque F, Raulet DH. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med (2010) 207:2065-72. doi:10.1084/jem.20100570.
68. Pradeu T, Jaeger S, Vivier E. The speed of change: towards a discontinuity theory of immunity? Nat Rev Immunol (2013) 13:764-9. doi:10.1038/nri3521.
69. Körner C, Altfeld M. Role of KIR3DS1 in human diseases. Front Immunol (2012) 3:326. doi:10.3389/fimmu.2012.00326.
70. Martin MP, Gao X, Lee J-H, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 31:429-34.
71. Pelak K, Need AC, Fellay J, Shianna KV, Feng S, Urban TJ, et al. Copy number variation of KIR genes influences HIV-1 control. PLoS Biol (2011) 9:e1001208. doi:10.1371/journal.pbio.1001208.
72. Boulet S, Sharafi S, Simic N, Bruneau J, Routy J-P, Tsoukas CM, et al. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS (2008) 22:595-9. doi:10.1097/QAD.0b013e3282f56b23.
73. Alter G, Rihn S, Walters K, Nolting A, Martin M, Rosenberg E, et al. HLA class I subtype dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute HIV-1 infection. J Virol (2009) 83(13):6798-805. doi:10.1128/JVI.00256-09.
74. Gaudieri S, DeSantis D, McKinnon E, Moore C, Nolan D, Witt CS, et al. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun (2005) 6:683-90. doi:10.1038/sj.gene.6364256.
75. Long BR, Ndhlovu LC, Oksenberg JR, Lanier LL, Hecht FM, Nixon DF, et al. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol (2008) 82:4785-92. doi:10.1128/JVI.02449-07.
76. Dring MM, Morrison MH, McSharry BP, Guinan KJ, Hagan R, Consortium IHR, et al. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci U S A (2011) 108:5736-41. doi:10.1073/pnas.1016358108.
77. de Vasconcelos JM, de Jesus Maués Pereira Móia L, Amaral Ido S, Miranda EC, Cicalisetakeshita LY, de Oliveira LF, et al. Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil. Genet Mol Biol (2013) 36:22-7. doi:10.1590/S1415-47572013000100004.
78. + T cell counts among African HIV-1 infected subjects with group B KIR haplotypes in the absence of specific inhibitory KIR ligands. PLoS One (2011) 6:e17043. doi:10.1371/journal.pone.0017043.
79. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity (1999) 10:661-71. doi:10.1016/S1074-7613(00)80065-5.
80. Wauquier N, Padilla C, Becquart P, Leroy E, Vieillard V. Association of KIR2DS1 and KIR2DS3 with fatal outcome in Ebola virus infection. Immunogenetics (2010) 62:767-71. doi:10.1007/s00251-010-0480-x.
81. Marcenaro E, Pesce S, Sivori S, Carlomagno S, Moretta L, Moretta A. KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts. Blood (2013) 121:3396-401. doi:10.1182/blood-2012-09-458752.
82. Ozturk OG, Gun FD, Polat G. Killer cell immunoglobulin-like receptor genes in patients with breast cancer. Med Oncol (2012) 29:511-5. doi:10.1007/s12032-011-9932-x.
83. Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia (2012) 26:296-302. doi:10.1038/leu.2011.180.
84. Gabriel IH, Sergeant R, Szydlo R, Apperley JF, deLavallade H, Alsuliman A, et al. Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood (2010) 116:2033-9. doi:10.1182/blood-2010-03-273706.
85. Karabon L, Jedynak A, Giebel S, Wolowiec D, Kielbinski M, Woszczyk D, et al. KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens (2011) 78:129-38. doi:10.1111/j.1399-0039.2011.01721.x.
86. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med (2012) 367:805-16. doi:10.1056/NEJMoa1200503.
87. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood (2009) 113:726-32. doi:10.1182/blood-2008-07-171926.
88. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 116:2411-9. doi:10.1182/blood-2010-05-283051.
89. McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol (2007) 68:309-23. doi:10.1016/j.humimm.2007.01.019.
90. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood (2009) 113:3119-29. doi:10.1182/blood-2008-06-164103.
91. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol (2002) 2:656-63. doi:10.1038/nri886.
92. Moffett A, Loke C. Immunology of placentation in eutherian mammals. Nat Rev Immunol (2006) 6:584-94. doi:10.1038/nri1897.
93. Male V, Sharkey A, Masters L, Kennedy PR, Farrell LE, Moffett A. The effect of pregnancy on the uterine NK cell KIR repertoire. Eur J Immunol (2011) 41:3017-27. doi:10.1002/eji.201141445.
94. Hiby SE, Apps R, Sharkey AM, Farrell LE, Gardner L, Mulder A, et al. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest (2010) 120:4102-10. doi:10.1172/JCI43998.
95. Xiong S, Sharkey AM, Kennedy PR, Gardner L, Farrell LE, Chazara O, et al. Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation. J Clin Invest (2013) 123:4264-72. doi:10.1172/JCI68991.
96. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med (2006) 12:1065-74. doi:10.1038/nm1452.
97. Rizzo R, Vercammen M, van de Velde H, Horn PA, Rebmann V. The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells. Cell Mol Life Sci (2011) 68:341-52. doi:10.1007/s00018-010-0578-1.
98. Rajagopalan S, Bryceson YT, Kuppusamy SP, Geraghty DE, van der Meer A, Joosten I, et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol (2006) 4:e9. doi:10.1371/journal.pbio.0040009.
99. Niepieklo-Miniewska W, Majorczyk E, Matusiak L, Gendzekhadze K, Nowak I, Narbutt J, et al. Protective effect of the KIR2DS1 gene in atopic dermatitis. Gene (2013) 527:594-600. doi:10.1016/j.gene.2013.06.015.
100. Hou Y-F, Zhang Y-C, Jiao Y-L, Wang L-C, Li J-F, Pan Z-L, et al. Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus erythematosus. Lupus (2010) 19:20-6. doi:10.1177/0961203309345779.
101. García-León JA, Pinto-Medel MJ, García-Trujillo L, López-Gómez C, Maldonado-Sanchez R, Fernández-Fernández ó, et al. Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients. Mol Immunol (2011) 48:1896-902. doi:10.1016/j.molimm.2011.05.018.
102. Gudjónsson JE, Karason A, Antonsdottir AA, Rúnarsdottir EH, Gulcher JR, Stefansson K, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol (2002) 118:362-5. doi:10.1046/j.0022-202x.2001.01656.x.
103. Luszczek W, Manczak M, Cislo M, Nockowski P, Wisniewski A, Jasek M, et al. Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum Immunol (2004) 65:758-66. doi:10.1016/j.humimm.2004.05.008.
104. Martin MP, Nelson G, Lee J-H, Pellett F, Gao X, Wade J, et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol (2002) 169:2818-22.
105. Bjorkstrom NK, Beziat V, Cichocki F, Liu LL, Levine J, Larsson S, et al. CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells. Blood (2012) 120:3455-65. doi:10.1182/blood-2012-03-416867.
106. Halary F, Peyrat MA, Champagne E, López-Botet M, Moretta A, Moretta L, et al. Control of self-reactive cytotoxic T lymphocytes expressing gamma delta T cell receptors by natural killer inhibitory receptors. Eur J Immunol (1997) 27:2812-21. doi:10.1002/eji.1830271111.